Technology and therapy leader in lung and heart assist becomes part of Germany’s largest medical device company
XENIOS, the technology and therapy leader in lung and heart assist, has been acquired by Fresenius Medical Care & Co, Germany’s largest medical device company. The closing of the transaction is subject to approval by the cartel authorities.
XENIOS is driving innovation in minimally invasive lung and heart assist, and is first to offer a complete product range that runs on a common platform. Fresenius Medical Care is a global market leader in dialysis, an extracorporeal medical procedure offering multiple analogies to lung support technologies.
'XENIOS will continue to manufacture and market its lung and heart assist product portfolio,' says Dr Boehm, co-CEO of XENIOS. 'Our strategy remains in place, and the processes and contacts remain unchanged.'
XENIOS’s Novalung product range for lung assist is a good match with renal dialysis. 'This acquisition is a unique opportunity for Fresenius Medical Care to add to its acute renal replacement offerings,' says Dr Georg Matheis, co-CEO of XENIOS. 'Fresenius Medical Care enables us to establish our innovative therapies worldwide, and together we will offer an unrivalled product range for organ assist.'
The integration of the expertise from XENIOS and Fresenius Medical Care is a sound basis to establish worldwide market leadership from renal to lung and heart assist. XENIOS‘s ongoing R&D projects including a wearable artificial lung will be continued.